Physician profile
Lori Storch Smith
NPI 1205834199
$1,106.33
in general payments reported to CMS, 2019-2025
15 companies · $381 in 2025
The $381 reported for 2025 was more than what 88% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.83 · 2020: $58.08 · 2021: $34.35 · 2022: $78.75 · 2023: $125 · 2024: $353 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $250.61 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Kaleo, INC. | $191.90 | 2019-2024 | Auvi-Q |
| Sanofi Pasteur INC. | $154.53 | 2024-2025 | |
| Pfizer INC. | $107.01 | 2024-2025 | |
| Seqirus USA INC | $80.28 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Glaxosmithkline, LLC. | $74.17 | 2024-2025 | Bexsero, Rotarix, Pediarix |
| Corium, LLC | $52.73 | 2022-2024 | Azstarys |
| Tris Pharma INC | $38.20 | 2019-2024 | Dyanavel Xr |
| Ars Pharmaceuticals Operations, INC. | $32.77 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $30.19 | 2024 | Qelbree |
| Alk-Abello, INC | $28.42 | 2025 | Neffy |
| Bavarian Nordic A/S | $16.88 | 2025 | Vivotif |
| Cranial Technologies, INC | $16.47 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.18 | 2020 | |
| Verrica Pharmaceuticals INC. | $15.99 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Storch Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.